Overview

Bioequivalency Study of Torsemide Tablets Under Fed Conditions

Status:
Completed
Trial end date:
2003-09-01
Target enrollment:
Participant gender:
Summary
The objective of this study was the bioequivalence of a Roxane Laboratories' Torsemide Tablets, 20 mg, to Demadex® Tablets, 20 mg (Roche) under fed conditions using a single-dose, 2-treatment, 2-period, crossover design.
Phase:
N/A
Details
Lead Sponsor:
Roxane Laboratories
Treatments:
Torsemide